The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board effective February 1, 2026, and designated him as the new Chief Executive Officer (CEO). He will succeed Matthias Gaertner, who will remain in office until December 31, 2025. This leadership transition marks a significant step for the company as it seeks to strengthen its position in the European Specialty Pharma sector.
Thomas Meier brings extensive experience from his tenure as CEO of Bachem Holding AG, a Swiss CDMO (Contract Development and Manufacturing Organization) listed on the stock exchange, where he served since 2020. Prior to that, he was Chief Operations Officer on the Executive Board of Bachem and worked as Head of Manufacturing at Peninsula Laboratories in San Carlos, California, USA, from 2001 to 2004. His background in operational leadership and growth management aligns with Medios' strategy to expand its footprint in individualized medicine and specialty pharmaceuticals.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, expressed confidence in the appointment: "With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers." He also thanked outgoing CEO Matthias Gaertner for his ten years of service, noting his decisive influence on the company's growth and success.
Meier commented on his new role: "I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios’ position in the European Specialty Pharma market." The appointment underscores Medios' commitment to advancing its mission of making innovative therapies accessible through its network of pharmacies, specialist practices, and pharmaceutical companies.
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company focuses on pioneering individualized medicine to deliver advanced treatments. As Germany's first listed specialty pharmaceutical company, its shares (ISIN: DE000A1MMCC8) are traded on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. For more information on individualized medicine, visit https://app.medios.group/en/individualizedmedicine.
The leadership change comes at a pivotal time, with important dates ahead for Medios in the 2025 financial year, including a quarterly statement on November 11 and participation in conferences such as mwb inspired Conference in Hamburg on November 12 and Berenberg European Conference in Fairmont Windsor Park, GB on December 4. The appointment of Meier is expected to drive capital-efficient growth and enhance shareholder value as Medios continues to expand its role in the specialty pharmaceutical supply chain.
